Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  Date:  November 20, 
2019  
Version: 1.2   
CONFIDENTIAL  
Page 1 CLINICAL STUDY PROTO COL  
A Phase 1 Randomized, Double Blinded, Placebo -Controlled Single Dose 
Escalation Study of OsrHSA in Adult Healthy Male and Female 
Volunteers  
This study will be conducted acc ording to this protocol, including protocol amendments and 
in compliance with Good Clinical Practice, the ethical principles, and other applicable 
regulatory requirements. 
Protocol Number : US-HY1001  
Clinical Phase :  Phase I 
IND Number:  19136  
Sponsor:  Wuhan Healthgen  Biotechnology Corporatio n 
Version : V 1.2 
Version Date:  11/20/2019  
CONFIDENTIAL  
This document contains confidential information, which should not be copied, referred to, 
released or published without written approval from  Wuhan Healthgen  Biotechnology 
Corporation .   In the event of any actual or suspected breach of this obligation, Wuhan 
Healthgen Biotechnology Corporation  must be promptly notified. These restrictions on 
disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL 
Page 2 TABLE OF CONTENTS 
TABLE OF CONTENTS ................................................................................................................ 3  
LIST OF TABLES ........................................................................................................................ 8  
LIST OF FIGURES  ...................................................................................................................... 8  
SPONSOR SIGNATURE  ............................................................................................................. 9  
INVEST IGATOR AGR EEME NT ............................................................................................ 10  
SPONSOR S TUDY  CONTACTS  .............................................................................................. 11  
LIST OF ABBRE VIATIONS AND DEFINITION OF TERMS ................................................. 12  
1 Protocol Summaries ............................................................................................................... 15  
1.1 Synopsis ................................................................................................................... 15  
1.2 Study Design Schema .............................................................................................. 19  
1.3 Schedule of Activities .............................................................................................. 20  
2 Introduction ............................................................................................................................ 22  
2.1 Background .............................................................................................................. 22  
2.2 Risk/Benefit Analysis .............................................................................................. 23  
2.3 Preclinical Studies .................................................................................................... 24  
 Non-clinical Pharmacology .............................................................................. 24  
 Non-clinical Pharmacokinetics ......................................................................... 24  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL 
Page 3 
 Safety Pharmacology and Toxicology .............................................................. 24  
3 Objectives and endpoints ....................................................................................................... 26  
3.1 Objectives ................................................................................................................ 26  
3.2 Endpoints ................................................................................................................. 26  
4 Study design ........................................................................................................................... 27  
4.1 Overall Study Design ............................................................................................... 27  
4.2 Study Process ........................................................................................................... 27  
 Definition of Dose Limiting Toxicity (DLT): .................................................. 28  
 Dose-escalation Criteria: ................................................................................... 28  
 Stopping Criteria: .............................................................................................. 29  
4.3 Rationale for Starting Dose Selection ...................................................................... 29  
5 Patient population .................................................................................................................. 30  
5.1 Number of Subjects and Description of Population ................................................ 30  
5.2 Inclusion Criteria ..................................................................................................... 30  
5.3 Exclusion Criteria .................................................................................................... 31  
5.4 Meals and Dietary Restrictions ................................................................................ 32  
5.5 Alcohol ..................................................................................................................... 32  
5.6 Activity .................................................................................................................... 33  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL 
Page 4 5.7 Randomization and Blinding .................................................................................... 33  
6 Study Intervention .................................................................................................................. 34  
6.1 Study Drug Description ........................................................................................... 34  
6.2 Study Drug Packaging and Labeling ....................................................................... 34  
 Drug Storage and Handling .............................................................................. 34  
 Study Drug Compliance and Accountability .................................................... 34  
 Disposal and Destruction .................................................................................. 34  
 Treatment Allocation and Administration, Dosing Regimen ........................... 34  
6.3 Duration of Treatment.............................................................................................. 35  
6.4 Removal from Study Treatment and off-Study Criteria .......................................... 35  
 Criteria for Removal from Study Treatment ..................................................... 35  
 Off-Study Criteria ............................................................................................. 35  
 Subject Replacement ......................................................................................... 36  
7 Study Assessment and Evaluations ........................................................................................ 38  
7.1 Description of Assessment Procedures .................................................................... 38  
7.2 Blood Samples for PK evaluations .......................................................................... 38  
7.3 Immunogenicity Evaluations ................................................................................... 38  
8 Data Collection and Management .......................................................................................... 39  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 5 8.1 Study Record Retentions ................................ ................................ ..........................  39 
8.2 Protocol Deviations  ................................ ................................ ................................ .. 40 
8.3 Publication and Data Sharing ................................ ................................ ...................  40 
9 Regu latory Human Subject Protection and Regulatory Oversight  ................................ ........  41 
9.1 Informed Consent Processes and Documentation ................................ ....................  41 
9.2 Confidentiality and Privacy  ................................ ................................ .....................  41 
9.3 Conflict of Interest  ................................ ................................ ................................ ... 42 
10 Safety Reporting  ................................ ................................ ................................ .............  43 
10.1  Definition of Adverse Event  ................................ ................................ ....................  43 
10.2  Causality of AEs  ................................ ................................ ................................ ...... 44 
10.3  Categorization of AEs  ................................ ................................ ..............................  44 
10.4  Reporti ng of SAEs and Suspected Unexpected Serious Adverse Reactions 
(SUSARs)  ................................ ................................ ................................ .............................  45 
10.5  IRB Reporting  ................................ ................................ ................................ ..........  45 
10.6  Quality Assurance and Quality Control  ................................ ................................ ... 46 
10.7  Study Monitoring Plan  ................................ ................................ .............................  46 
10.8  Study C losure  ................................ ................................ ................................ ...........  47 
10.9  Safety Review Committee (SRC)  ................................ ................................ ............  47 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL 
Page 6 11 Statistical Considerations ................................................................................................ 49  
11.1  General Statistical Considerations ........................................................................... 49  
11.2  Determination of Sample Size ................................................................................. 49  
11.3  Population Analysis ................................................................................................. 49  
 PK and PD Population ............................................................................... 49  
 Safety Population ....................................................................................... 49  
11.4  Statistical Analysis ................................................................................................... 50  
 PK Analysis ............................................................................................... 50  
 Safety Analysis .......................................................................................... 50  
 Immunogenicity Analysis .......................................................................... 51  
11.5  Tabulation of Individual Participation Data ............................................................ 51  
12 References  ....................................................................................................................... 52  
 
  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 7 LIST OF TABLES  
Table 1 Schedule of Activities  ................................ ................................ ................................ ..... 20 
 
LIST OF FIGURES  
Figure 1 Study Design Schema  ................................ ................................ ................................ ..... 19 
 
  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 8 SPONSOR SIGNATURE  
 
Study Title :  
A Phase 1 randomized, double blinded, placebo -controlled single dose escalation study of 
OsrHSA in adult healthy male and female volunteers  
 
 
Protocol Number : US-HY1001  
 
Version : 1.2 
 
Person authorized to sign the protocol and protocol amendment(s) for the Sponsor,  
Qinhui Song   MD, PhD ____________________________________  
 
 
Signature  by:  
 
____________________________________  
Date : November 20, 2019  
  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 9 INVEST IGATOR AGR EEMENT 
 
I have read Protocol “A Phase 1 randomized, double blinded, placebo -controlled single dose 
escalation study of OsrHSA in adult healthy male and female volunteers ” and agree to condu ct 
the study as described therein in compli ance with ICH Guidelines for Good Clinical Practice and 
applicable regulatory requirements and to in form all who assist me  in the condu ct of this stu dy of 
their responsibiliti es and obli gations.  
The signature below constitut es my agreement to the  contents of  this p rotocol (version 1.2, 
date November 20, 2019 ). 
 
__________________________________________________________  
Signature          Date  
 
__________________________________________________________  
Name (please type or print)  
David Nguyen, MD  
__________________________________________________________  
Institution  
WCCT Global, Inc.  
__________________________________________________________  
Address  
5630 Cerritos Ave.  
Cypress, CA 90630  
USA  
  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 10 SPONSOR  STUDY  CONTACTS  
 
Name  Title/Role  Contact Information  
QINHUI SONG  CMO Tel:  086-27-59403931(O)  
086-13689001185(Cell)  
Email: sqhui@oryzogen.com  
WEITAO WU  Medical Director  Tel:  086-18710439305  
Email:  wwtao@oryzogen.com  
   
 
 
 
 
 
 
 
 
 
 
  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 11 LIST OF ABBREVIATIONS  AND D EFINITION OF  TERMS  
AE Adverse Event 
ALP  Alkaline  Phosp hatase  
ALT  Alanine  Transaminase   
ANC  Absolute number of neutrophils  
aPTT  Activated  Partial  Thromboplastin  Time  
AST  Aspartate  Transaminase  
AUC  Area Under the Curve  
BP Blood Pressure 
BUN  Blood Urea  Nitrogen  
CBC  Complete  Blood  Count  
CMP  Comprehensive Metabolic Panel  
CNS  Central Nervous System  
ConMeds  Concomitant medications  
CRF (eCRF)  Case Report Form (Electronic Case Report Form) 
CRO  Contract Research Organization 
CSR  Clinical study report   
CT Computed Tomography  
DLT Dose  Limiti ng Toxicity  
DNA  Deoxyribonucleic acid  
DP Drug Product  
ECG Electrocardiogram 
ECOG  Eastern Cooperative Oncology Group  
EDC  Electronic Data Capture  
EOS End-of-Study  
EOT  End of Treatment  
FDA Food and Drug Administ ration 
GCP Good Clinical Practice 
G-CSF  Granulocyte Colony -Stimulating Factor  
GI Gastrointestinal  
GLP  Good Laboratory Practice  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 12 GMP  Good Manufacturing Practice  
H1 Histamine -1 
HbcAb  Hepatitis B core antibody  
HBsAg  Hepatitis B Surface antigen  
HBV  Hepatitis B virus  
HCV  Hepatitis C virus  
HIV  Human immunodeficiency virus  
HNSTD  Highest noseverely toxic dose  
HR Heart rate 
IB Investigator’s Brochure 
IBD Inflammatory Bowel Disease  
IC50  Half maximal inhibitory concentration  
ICF Informed Consent Form        
ICH  International Conference on H armoni zation 
IEC Independent Ethi cs Committee 
IgG Immunoglobulin G  
INR International  Normalized  Ratio  
IRB Institution al Review Board 
IRR Infusion Related Reaction  
IUD intrauterine device  
IUS Intrauterine system  
IV Intravenously  
IVIG  IV immunoglobulin  
MCH  Mean Corpuscular Hemoglobin  
MCHC  Mean Corpuscular Hemoglobin Concentration  
MCSF  Macrophage Colony -Stimulating Factor  
MCV  Mean Corpuscular Volume  
MedDRA  Medical Dictionary for Regulatory Activiti es 
MRI Magnetic Resonance Imaging  
MRSD  Maximum Recommended Starting Dose   
Nabs  Neutralizing antibodies  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 13 NYHA  New York Heart Association  
PDF  Portable Document Format  
PDX  Patient derived xenograft  
PE Physical examination  
PET  Positron emission therapy  
PK Pharmacokinetics  
PT Prothrombin time  
QA Quality assurance  
QC Quality control  
QTcF  QT-interval corrected according to Fridericia's formula  
RBC  Red blood cells  
RDW  Red Cell Distribution Width  
REB  Research Ethics Board  
RNA  Ribonucleic acid  
SAE Serious Adv erse Event 
SMP  Study Monitoring Plan  
SOC  System organ class  
SOP  Standard Operating Procedures  
SPR  Surface plasma resonance  
SRC  Safety Review Committee  
SUSARs  Suspected Unexpected Serious Adverse Reactions  
TCR  Tissue cross -reactivity  
TEAE Treatment Em ergent Ad verse Event  
TK Toxicokinetics  
ULN Upper Limit of  Normal 
UPCR  Urine Protein  to Creatinine  Ratio  
WBC  White Blood  Cells  
 
  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 14 1 PROTOCOL SUMMARIES  
1.1 Synopsis  
Title:  A Phase 1 randomized, double blinded, placebo -controlled single 
dose escalation study of OsrHSA in adult healthy male and female 
volunteers   
Sponsor : Wuhan Healthgen Biotechnology Corporation  
  
Study Drug : OsrHSA  (Recombinant Human Albumin from Oryza sativa ) for 
infusion  
Normal Saline (0.9% Sodium Chloride) will be used as the placebo  
Clinical Trial Phase : Phase 1 
Proposed Indication : Circulatory dysfunction due to hypovolemia , including patients 
with cirrhotic ascites and hypoalbuminemia  
 
Primary Objectives:  
 
  
• To assess the safety and tolerability profile of  OsrHSA  
when administered as single dose IV infusion  
  
Secondary Objectives:  
  
• To characterize the pharmacokinetics (PK) of OsrHSA  
when administered as single dose IV infusion  
• immunogenicity profiles  of OsrHSA  when administered as 
single dose IV infusion  
 
Exploratory To assess  changes in serum albumin level, colloid  osmotic 
pressure, blood pressure and body weight when 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 15 Objectives:  
 administered as single dose IV infusion   
Study Population:  Healthy  male and female volunteers,  non-smokers , 18-55 years of 
age 
  
Number of Subjects 
planned : Up to 40 subjects , additional subjects might be rec ruited depending 
on emerging data from current study and the ongoing trial in China   
Number of Study 
Centers Planned : One study site located in the United States  
 
Study Design : This is a Phase 1  randomized, double blinded, placebo -controlled,  
single dose escalation study  to evaluate safety, tolerability, PK, and 
immunogenicity of OsrHSA in healthy volunteers (See study 
design schema ).  
After a screening period of up to 28 days, the qualified subjects will 
be randomized to OsrHSA or placebo (6:2). Each e nrolled subject 
will receive one single  assigned dose of OsrHSA or placebo . The 
investigator and subjects will be blinded to treatment as signment. 
During the study, subjects will be evaluated for safety and 
tolerability , PK/PD, and activity of OsrHSA.  
On day 1, OsrHSA or placebo  will be administered as single IV 
infusion at a rate lower than 2 ml/min to the subjects. Patients will 
be observ ed overnight. On Day 2, after completion of the study 
procedures and assessments, subjects will be discharged from the 
clinical research center. Seven -day dose -limiting toxicity (DLT) 
observational period will commence upon completion of dosing  at 
the end of infusion (EOI).  Subjects will have end -of-study (EOS) 
follow -up visits on Day 30 after infusion . 
The planned doses are 20, 40, 80, 140,  and 200 mg/kg, dose 
level(s) higher than 200mg/kg might be an option(s) based on 
emerg ing data from this study and ongoing China clinical trial
（China IND#: CXSL1500135; Protocol Number: HY1001 ）.  
 
 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 16 Dose escalation decisions will be determined based on toxicities  
data as well as available all available PK data observed within 7 
days after dosing.  
 
Study participation 
Duration:  The screening period is up to 28 days, one treatment day, and 
follow -up period of 30 days  
 
Pharmacokinetic (PK) 
evaluations : Blood samples for single dose PK will be collected from all 
subjects to determine the albumin concentration changes , they will 
be taken at time points listed in Table 1 . The PK of OsrHSA will 
be analyzed using standard non -compartmental analysis (NCA) by 
validated software WinNonLin version 6.4 or higher (Certara, NJ, 
USA). PK parameters derived from NCA ana lysis will include, but 
not limit to, AUC 0-∞ and AUC 0-t, Cmax, t1/2, CL, and V d. PK 
parameters will be listed for each subject and summarized with 
descriptive statistics by each dose level/cohort.  PK parameters will 
also be presented with baseline correcte d. 
Blood samples for immunogenicity will be collected at time points 
shown in Table 1 . Neutralization activity will be evaluated if ADA 
is positive.  
 
Safety Evaluations : The safety population will consist of all subjects who are infused  
the study drug and have at least one post -dose safety assessment.  
Safety will be assessed by physical examinations, vital signs, 
electrocardiograms, AEs monitoring.  AEs are graded per Guidance 
for Industry Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical 
Trials .  
Efficacy Evaluations : The parameters including, but not limited to, serum albumin level, 
colloid osmo tic pressure, blood pressure, 24 -hour fluid input and 
urine output, and body weight will be measured at baseline and at 
time points listed in Table 1 . The changes in serum albumin level, 
colloid osmotic pressure, blood pressure, body weight and other 
parameters will be assessed.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 17  
Immunogenicity : Blood samples for immunogenicity will be collected  until 30 days 
after the infusion   
Statistical Analysis:  All PK, immunogenicity, safety and efficacy data will be 
summarized using descriptive statistics (number of subjects, mean, 
median, standard deviation, minimum, and maximum) for 
continuous variables and using frequencies and percentages for 
discrete variab les.   
 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 18 1.2 Study Design Schema  
Figure 1 

Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 19 1.3 Schedule of Activities   
a. Screening procedures will be performed at screening visits from D -28 to D -2, including ultrasound, smoking, alcohol, drug 
use test, serum albumin. Pre -dose from D -1 to infusion, smoking, alcohol, drug use test, serum albumin will be performed 
again. (The two times serum albumin average will be used as subject’s baseline serum albumin ) 
b. Urine collection will be performed 24hr after infus ion 
c. The 0.5h time point after dose initiation will change to ± 5 minute window (instead of ± 2m inute ).   
d. The D3 and D5 time points will change to ± 6 hour  window (instead of ± 4h)  
e. Abdominal ultrasound exam will be performed and reviewed during the 28 day s creening period, prior to patient check -in 
on Day -1 
f. Alcohol and Cotinine will be tested at all follow -up visits (D3, D5, D8, D15, D22, D30)  
g. Syphilis will be tested at the screening timepoint, in order to adhere to the new exclusion criteria described abov e 
h. Anti-HCP antibody  will be measured at the same time points as ADA  
i. In order to calculate accurate creatinine  clearance, subjects’ body weight will be re -measured at Day 8 and Day 30 visits.  
j.  
 
Table 1 Schedule of Activities  
Protocol   Activity   Clinical Research Unit (CRU) Confinement  Outpatient Visits  
 Scree
n 
-D28 
to  
– D2 Pre-
dose  
-D1 
to 
dose  Dose 
initiation  
 0.5 h ± 
5m after  
Dose  
initiati on 1.0h ± 
10m 
after 
Dose 
initiation   
EOI+
10m 0.5h 
Post 
EOI 
± 
10m 4h 
± 
10m 12h  
± 
10m D2 
24h  
± 30m  D3 
± 6h D5 
± 6h D8 
± 1d D15 
± 2d D22 
± 2d D30 
± 2d 
Signed Informed Consent 
(ICF)1 ×                
Inclusion/Exclusion Criteria  × ×               
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 20 Protocol   Activity   Clinical Research Unit (CRU) Confinement  Outpatient Visits  
 Scree
n 
-D28 
to  
– D2 Pre-
dose  
-D1 
to 
dose  Dose 
initiation  
 0.5 h ± 
5m after  
Dose  
initiati on 1.0h ± 
10m 
after 
Dose 
initiation   
EOI+
10m 0.5h 
Post 
EOI 
± 
10m 4h 
± 
10m 12h  
± 
10m D2 
24h  
± 30m  D3 
± 6h D5 
± 6h D8 
± 1d D15 
± 2d D22 
± 2d D30 
± 2d 
Demographics2 ×                
Weight3 × ×        × ×  x   x 
Medical History4 × ×         × × × × × × 
Physical Examination5 × ×    × × × × × × × × × × × 
Current 
Medications/OTC/suppleme
nts × ×  
  
        ×  × 
Vital Sig ns6 × ×  × × × × × × × × × × × × × 
12 Lea d Electrocardiogram 
(ECG)7 × ×   × × × × × × × × × × × × 
Abdominal  Ultrasound)8 ×                
Adverse Events (AE)  Ongoing  
Laboratory Tests  
Urine Drug Screen  × ×               
Alcohol Breath Test  × ×         × × × × × × 
Urine Cotinine Test  × ×         × × × × × × 
Pregnancy Test for Female9 × ×            ×  × 
Ig E and Ig G Against Rice  ×        ×  × ×  ×  × 
Hemato logy & Serum 
Chemistry10 × ×     ×   ×   ×   × 
Coagulati on Tests  ×            ×    
Screening for HIV, HBV, 
HCV,  Syphilis 11 ×                
Urine Analysis (U/A)12 ×      × × × × × × × × × × 
Study Drug Administration    ×              
Injection Site Reaction   ×  ×  × ×  × ×       
Pharmacokinetics (PK)13  ×  ×  × × × × × × × × × × × 
Colloid Osmotic Pressure14 
  ×  ×  × × × × × × × × × × × 
Anti -Drug  Antibodies 
(ADA); Anti -HCP antibody 
15  ×  
  
       × × × × 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 21 Abbreviat ions: ADA = anti -drug antibody; EOI=End of Infusion; EOS=End of Study; EOT=End of Treatment; ECO G = Easter n Cooperativ e Oncolog y Group ; 
ConMeds = Concomitant medications; CT  = computed  tomography;  MRI = magnetic resonance  imaging; HIV  = human  immunodeficiency  virus;  HBV  = 
hepatitis B virus; HCV  = hepatitis C virus; PD = pharmacodynamics ; PK = pharmacokinetics  
1. Written consent must be obtained prior to performing any protocol specific procedure.  
2. Age, height, gender, ethnicity, and race at screening where possible.  
3. Body weight will be measured at screening, predose and postdose at Day 2,  D 3, Day 8 and Day 30 visits  ..  24-hour liquid input (drinking water) and output 
(urine) will be recorded post EOI 
4. Medical History:  includes any significant or relevant diseases, surgeries, or other medical events during the past 5 years a nd any new conditions arising while 
enrolled in the study.  
5. PE: Full physical examination including the cardiovascular, pulmona ry, GI, and nerve system, and skin will be performed at screening and EOS visits, and partial 
physical examination can be done at other visits to assess any abnormalities or change from baseline, including focused skin and cardiopulmonary examination.  
6. Vital signs include temperature, pulse, respiratory rate, and blood pressure. Vital signs will be assessed at screening and on t he visits at the clinical  research unit. 
Vital sign will be performed within 30 minutes prior to the infusion, at the EOI (+ 5 minu tes) and before every PK sampling. Additionally, blood pressure will be 
measured every 10 minutes during infusion, every  30 min post EOI up to 6 hours, every 1 hour after 6 hours up to 12 hours post EOI, and every 2 hours until 24 
hours post EOI or dischar ge, and at every outpatient visit . Blood pressure should be measured prior to Colloid osmotic pressure sampling when blood pressure 
measuring and colloid osmotic pressure sampling are specified to be done at the same time.  
7. ECGs (12 lead ) will be collected  at screening, predose , during infusion (1hr) ,and EOI,  prior to PK sampling during Day 1, and as clinically indicated, and at EOS.  
8. Abdominal ultrasound exam will be performed and reviewed during the 28 day screening period, prior to patient check -in on Day -1 
9. Only in women of childbearing potential. Urine pregnancy test will be done at screening and EOS, serum pregnancy test will be  done pre -dose and on D15, or as 
clinically indicated.  
10. Hematology includes Complete blood count (CBC) (hematocrit (HCT), hem oglobin, red blood cells (RBC), Red Cell Distribution Width (RDW), Mean 
Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC), platelets, whi te blood cells (WBC) 
with absolute differential counts of n eutrophils, lymphocytes, monocytes, eosinophils, and basophils).  Serum Chemistry ALT, AST, ALP, K+, Na+, Cl -, Ca2+, 
TBIL, blood urea nitrogen (BUN) or urea, creatinine, uric acid, glucose (non -fasted).  
11. HIV screening (Antigen/antibody test), HCV antibodie s, hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti -HBs), total hepatitis B core antibody 
(anti-HBc), IgM antibody to hepatitis B core antigen (IgM anti -HBc),  Syphilis .  
12. Twenty -four hours urine for D1 after the administration will be collected for 24 hours urine protein. Dipstick  is acceptable for other time points.  Microscopic  analyses  if 
clinically  indicated.  If ≥ 2+ protein on  urine  dipstick,  then collect  spot urine  sample  to calculate  urine  protein  to creatinine  ratio (UPCR)  or collect  24h urine.   
13. PK samples (Serum albumin) will be collected at pre -dose, 0.5h after dose initiating, EOI, and 0.5h, 4h, 12h, 24h (Day 2), 48h (Day 3), Day 5, Day 8, Day 15, Day 
22, and Day 30 post EOI. The exact/actual time to collect blood will be documented.  
14. Colloid osmotic pressure will be measured within 30 min predose,  every 30 min after dose initiating until EOI, EOI, every 1 hour up to 6 hours post EOI, every 2 
hour after 6 hours up to 12 hours post EOI, and every 4 hours until 24 hours post EOI or discharge, 48h (D3), D5, D8, D15, D2 2, and D30 post EOI. Blood 
pressure should be measured prior to each colloid osmotic pressure sampling.  
15. Blood samples for ADA  and Anti-HCP antibody  analyses will be collected at pre -dose, D8, D15, D22,  and D30 post EOI.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 22 2 INTRODUCTION  
2.1 Background   
Human serum albumin (HSA), the main protein of human blood plasma , is a soluble, globular, 
and unglycosylated monomeric protein. It is respo nsible for 70 -80% of colloid pressure of 
normal plasma, thus  plays a primary  role in regulating blood volume by maintaining the colloid 
osmotic pressure and stabilizing extracellular fluid volume . HSA also  functions as a carrier 
protein for steroids, fatty  acids, hormones, and small molecules  (1).  
Clinically , HSA is widely used for restoration and maintenance of circulating blood volume 
where volume deficiency has been demonstrated and use of a colloid is appropriate, such as adult 
respiratory distress syndrome , hypo volemia, large-volume paracentesis, ovarian hyperstimulation 
syndrom e, plasma exchange, and ascites caused by cirrhosis of the liver (2, 3). Moreover, HSA is 
also used as an excipient for vaccines or therapeutic protein  drugs and as a cell culture medium 
supplement in the production  of vaccines and pharmaceuticals (4). Man y other novel uses for  
HSA in biological applications have recently been explored, such  as carrier of oxygen (5), 
nanodelivery of drugs (6), and fusion  of peptides (7).  Currentl y, clinical used  production of  HSA 
is primarily based on collected human plasma , which raises a public health concern with plasma -
derived HSA (pHSA) with its potential risk for transmission of blood -derived  infectious 
pathogens , such as bacteria  (syphilis, Chagas disease) , viruses  (including but not limited to HBV, 
HCV, HIV, HTLV, West Nile virus, CMV)  and prions  (Mad Cow Disease)  (9, 10) . The market 
demand for HSA is estimated around  1000（Human Serum Albumin Market In -deep Analysis 
and Experts Review Report 2019 -2024） tons per yea r worldwide . It was reported that the 
shortage of human plasma led to  a rapid increase in price of HSA, which in turn resulted in fake  
albumin appearing on the market (8). In fact,  illegal plasma collection has caused HIV to spread 
rapidly, creating  what a re known as AIDS villages in Henan Province in  China (11).  
The develop ment  of screening has been greatly decreased the risk for transmission of blood -
derived  infectious pathogens , however , the risk has never been eliminated  and is always  there . 
To eliminate the potential risk of viral contamination,  regulatory agencies in some have 
encouraged pharmaceutical companies  to use non –animal -derived sources for pharmaceutical  
production (12). Thus , the development of a low -cost method for  the production of recombinant 
HSA (rHSA) is essential as a  safer and potentially unlimited alternative to pHSA.  
Over the past decades, various expression systems have been used to produce rHSA, including 
Escherichia coli (13), Saccharomyces cerevisiae (14), Kluyveromyces lactis (15), Pichia pastoris 
(16), transgenic animals (17), and transgenic plants (18 –21). Attem pts to produce rHSA in 
tobacco leaves and potato tubers achieved expression levels of 0.02% of total soluble protein 
(TSP) (18), and expression was increased to 0.2% of TSP by targeting the rHSA to the apoplast 
of potato tubers (19). Recently, an expressio n level of 11.1% of TSP was obtained by expressing 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 23 rHSA in tobacco leaf chloroplasts (20). More recently, an rHSA expression level of 11.5% of 
total proteins was achieved in a rice cell culture by a sugar starvation -induced promoter (21 ). 
Although  rHSA has  been successfully expressed in these systems,  none of them has proven to be 
cost-effective at large scale.  
Plant seeds, especially cereal crop seeds, are promising vehicles for producing recombinant 
proteins, because they can  achieve high accumulation of recombinant protein, display high levels 
of protein stability, stored for long periods of time, and are well controlled on a production scale 
(22, 23). Human lysozyme and lactoferrin produced for oral administration have been 
successfully expressed in rice  seeds (24, 25). Here,  Healthgen  developed  rice seeds as a 
bioreactor for large -scale production of Oryza sativa recombinant HSA (OsrHSA). OsrHSA can 
be highly and stably expressed in rice seeds and can be processed cost -effectively. OsrHSA was 
found to be  equivalent to pHSA in terms of biochemical properties, physical structure, functions, 
and immunogenicity.  
2.2 Risk/Benefit Analysis  
Potential risks to subjects receiving OsrHSA  are considered to be similar to  pHSA , which have 
been shown to be well -tolerated in general. As there is  no difference  in in vivo  efficacy, 
immunopharmacological activity,  safety pharmacology, toxicology, and pharmacokinetic 
profiles  observed between OsrHSA and HpHSA, OsrHSA is expected to h ave similar clinical 
effects as HpHSA  in indications  that are currently  approved for HpHSA.  
Furthermore, a randomized, double blinded, pos itive-controlled Phase 1 single dose and dose 
escalation study to evaluate safety, tolerability, PK and PD (PK/PD) of OsrHSA in adult healthy 
volunteers  (IND Number: CXSL1500135; Protocol Number: HY1001)  is ongoing  in China . The  
planned dose levels in this study are 2.5, 5, 10, 15 and 20 g , IV, which are equal to 35.7, 71.4, 
142.9, 214.3, and 285.7 mg/kg respectivelly, assuming a body weight of 70 kg.  
The current available data of dose level of 2.5 g (35.7 mg/kg assuming body weight of 70 kg)  
have been show ing an  acceptable safety profile . Five subjects have received 2.5 grams , IV, 
OsrHSA in clinical trial in China. The data indicated that ADA  and anti-HCP antibody were 
negative at 85 days ( 5 subjects)  of post -dosing. No cytokines promotion was found at 28 days ( 5 
subjects)  of post -dosing. No allergic and hypersensitivity  symptom was observed during or at 
post-dosing. One subject with SAE of ALT, AST and GGT increasing was observed at 7 day of 
post-dosing. This subject had a gall -stone with size 1.5*1.4cm  in cystic duct  by ultrasound 
examination. He was  diagnosed a biliary obstruction  cholecystitis with gall -stone. The subject 
recovered after 7 days of the symptom  and left the investigative center. The safety assessment of 
SAE was performed by DSMB. The conclusion is that the SAE was caused by biliary obstruction  
cholecystitis. It is most likely no relevant to OsrHSA. The current data from clinical trial in the 
China indicated that the risks to subjects r eceiving OsrHSA is acceptable.  
Additional safety and PK /PD data from the Phase 1 study ongoing in China will be provide once 
available.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL
Page 24 2.3 In summary, the risk/benefit balance is considered acceptable to administer OsrHSA 
to healthy volunteers. Preclinical Studies 
 Non-clinical Pharmacology 
The nonclinical pharmacology program for OsrHSA has been designed to evaluate the in vivo  
efficacy, immunopharmacological activity and safety profiles in animals to predict the 
pharmacologic profile of OsrHSA in human. T he in vivo  efficacy of OsrHSA was evaluated in 
the treatment of ascites of high-fat diet induced hepatic cirrhosis in a Wistar rat model, as well as in hemorrhagic shock model using male Japanese rabbits. Similar efficacy of OsrHSA and HpHSA has been demonstrated in these two animal disease models. 
The effects of OsrHSA on the immune function of mammalian systems were investigated in 
three studies. No active systemic anaphylaxis (ASA) reaction was induced in rabbits, after primed with OsrHSA/CFA and challenged with OsrHSA/IFA, with, no elevated total IgG, IgM, IgA, IgE production detected. No passive cutaneous anaphylaxis (PCA) induced in the guinea pigs after transfer the sensitized serum from the rabbits. 1/1436 and 0/200 anti-HCP IgE 
antibody was detected in a preliminary non GLP study and an US-GLP study, suggesting a low risk of the HCP from Oryza sativa  in inducing allergic responses in humans. T-cell mediated 
DTH study confirmed that OsrHSA and HpHSA were weakly immunogenic in soluble forms as a foreign antigen to mice.  If administered as soluble proteins, OsrHSA was unable to induce DTH response in mice, which suggested a low risk of inducing type IV hypersensitivity in human subjects. 
 Non-clinical Pharmacokinetics 
The pharmacokinetic (PK) and toxicokinetics (TK) profiles of OsrHSA were characterized in 
rats and monkeys following intravenous administration, which is the intended route of administration in human. In order to distinguish exogenous OsrHSA from endogenous rat serum albumin, OsrHSA was labeled with 
125I by Chloramine-T method before administration. 
Distribution, metabolism and excretion was evaluated in the single-dose PK study in rats. 
OsrHSA is expected to behave like HSA, an endogenous protein, in drug transportation as well 
as in interactions with CYP enzymes or other drug transporters. Therefore, no pharmacokinetic drug interaction studies of OsrHSA were conducted. 
HpHSA was included as a benchmark control and compared with OsrHSA side-by-side in 
several pharmacokinetic and toxicokinetics studies. HpHSA and OsrHSA showed similar PK and TK profile among all the studies, except HpHSA showed stronger immunogenicity in rats following repeat dose administration. 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL
Page 25 
 Safety Pharmacology and Toxicology 
Safety pharmacology was conducted in mice to evaluate the effect on CNS function, as well as in 
cynomolgus monkeys to evaluate the effect on cardiovascular and respiratory functions. HpHSA was included as a control in all these studies to detect off-target or impurity induced side effects. 
Because of pre-clinical and clinical experiences over many years of using with HpHSA, the full 
battery of toxicology studies conducted were not to evaluate the pharmacological and toxicological effects of the active ingredient albumin in OsrHSA, but mainly to evaluate unexpected toxic activities due to the impurities in the OsrHSA drug product. Evaluation of the potential risk to humans receiving OsrHSA was conducted in a series of US-GLP compliant 
toxicology studies according to 21 CFR 58. 
While albumin are variable among the species, the tertiary structures and biological functions are 
highly conserved ( Nurdiansyah, R., Rifa’I, M. 2016 ). Since the MOA of albumin for treatment of 
circulatory dysfunction is attribute to the increase of plasma volume, which is similar among species, therefore, multiple species (both rodent and non-rodent) were included in the toxicology evaluation. 
Single-dose study in rats, 2-week repeat-dose with 4-week recovery phase studies in rats and 
monkeys were conducted to assess the toxicity and toxic organs as well as the reversibility, persistence, or delayed occurrence of any safety findings. Among these studies, the toxic levels and toxic organs identified were similar in animals treated OsrHSA and HpHSA. The treatment-
related clinical and pathological changes were directly resulted from the biologic functions of albumin, and the daily injection induced fluid overload and increased blood pressure. No OsrHSA specific toxicity was identified, indicating the entire formulation of OsrHSA, including all possible impurities, exerted similar biological function, as well as toxicity at high dose, as that of the formulation of HpHSA. Both OsrHSA and HpHSA were immunogenic in animals via i.v. 
dosing. Formation of ADA was prevalent in rats and monkeys, although no impact on TK or systemic exposures were observed. Regardless with HSA formulation administered, ADA formed can be cross-recognized by the other HSA reagent, indicating that these ADA were 
against the same epitopes common in both OsrHSA and HpHSA, further supported the tertiary structure similarity between OsrHSA and HpHSA. 
A full battery of study was conducted to evaluate the genotoxicity of OsrHSA as required in ICH 
S2 (R1) on Genotoxicity testing and Data Interpretation for Pharmaceuticals Intended for Human 
Use, June 2012. Ames test, chromosomal aberration test as well as in vivo micronucleus study 
confirmed that OsrHSA has no potential genotoxicity. 
Host cell protein (HCP) is the main impurity in the formulations of OsrHSA. The potential 
toxicity and immunogenicity induced by HCP was evaluated in a 2-week daily repeat i.v. dose 
non-GLP study in SD rats. No clinical findings were observed for 25 µg/kg HCP, that is equivalent to the possible HCP presented in 5 g/kg OsrHSA.
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 26 3 OBJECTIVES  AND ENDPOINTS  
3.1 Objective s 
Primary Objectives:  
• To assess the safety and tolerability profile of  OsrHSA  when IV administered  as single 
dose  
Secondary Objectives:  
• To characterize the PK of OsrHSA  when IV administered as single dose  
• Immunogenicity profiles  of OsrHSA  when IV administered as single dose   
 
Exploratory Objectives:  
• To assess  changes in serum albumin level, colloid  osmotic pressure, blood pressure and 
body weight when IV administered as single dose   
3.2 Endpoints  
Primary Endpoints  
1) Safety and tolerability profile including adverse events, changes in safety assessment 
param eters (e.g. vitals, ECGs, clinical laboratory results)  
Secondary Endpoints  
1) PK parameters: AUC 0-∞ and AUC 0-t , Cmax, t1/2, CL, V ss, etc.  
2) ADA : Samples confirmed to be positive for ADA will be further tested for NAb.  
Exploratory Endpoints  
• Changes in serum albumin level and colloid osmotic pressure  
• Changes in body weight and blood pressure  
 
 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL
Page 27 4 STU DY DESIGN 
4.1 Overall Study Design 
This is a Phase 1 randomized, double blinded, placebo-controlled, single dose escalation study in 
healthy volunteers to evaluate safety, tolerability, PK, PD and immunogenicity of OsrHSA (See 
study design schema ).  
4.2  Study Process 
The trial will include a screening period, treatment period, and follow -up period of 30 days 
after administration . The screening period will be up to 28 days prior to investigational product 
administration. The screening process will initiate  upon completion of the informed consent 
process. Once consent is provided by each participant , a thorough screening process will take 
place , including detailed medical history, physical examination, vital signs, concomitant 
medications, safety labs (see T able 1), 12 lead electrocardiogram, urine  pregnancy test, 
urinalysis, serology panel (refer Table 1), assessment of inclusion and exclusion criteria.  Upon 
completion of the screening , qualified subjects will be randomized to OsrHSA or placebo (6:2). 
Each enrolled subject will receive one single assigned dose of OsrHSA or placebo. The 
investigator and subjects will be blinded to treatment assignment. During the study, subjects will be evaluated for safety and toxicity, PK/PD, and activity of OsrHSA. 
OsrHSA or placebo will be administered as single IV infusion at a rate lower than 2 ml/ min to 
the subjects. The actual start and stop times of the infusions, along with any interruptions in the infusion will be recorded. Subjects will have end-of-study (EOS) follow-up visits on Day 30 
after infusion. 
The planned doses are 20, 40, 80, 140, and 200 mg/kg (Table 2), dose level(s) higher than 200 
mg/kg might be an option(s) based on emerging data from this study and ongoing China clinical 
trial, if that is the case, an amendment will be submitted. 
The protocol for the repeat dose study will be submitted as an amendment to the IND after the 
single dose study has been completed and analyzed. The dose schedule of the repeat dose study will be based on results obtained from the single dose study. The safety of the dose that will be used in the repeat dose study will be established before the initiation of the repeat dose study. 
Dose escalation will occur sequentially after review of safety data for each dosing cohort by the 
safety review committee (SRC). Dose escalation to the next dose level will proceed uninterrupted as long as no pre-defined DLT or stopping criteria are met. 
 Definition of Dose Limiting Toxicity (DLT): 
AEs will be graded according to the FDA Guidance for Industry Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials . DLT is 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL
Page 28 defined according to the criteria below as any TEAEs occurring during the DLT observation 
period (7 days) and considered to be related to OsrHSA: 
Any Grade≥ 3 AE or laboratory abnormality as defined in the FDA Guidance for Industry 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials 
All Grade 3 toxicities for vital signs and laboratory parameters must be confirmed with a repeat 
measurement obtained within 1 hour or as soon as possible for vital signs and within 24 hours for 
laboratory parameters.  
 
Table 2 Dose Escalation Schedule 
Dose Escalation Level  Dose  (mg/kg ) Subjects  
(OsrHSA:placebo)  
cohort 1  20, IV  8(6:2)  
cohort 2  40, IV  8(6:2)  
cohort 3  80, IV  8(6:2)  
cohort 4 140, IV 8(6:2)  
cohort 5 200, IV 8(6:2)  
 
 Dose-escalation Criteria: 
Tolerability and safety of subjects in a cohort will be reviewed by the SRC which is comprised 
of an independent Medical Monitor, site Principal Investigator, and Sponsor Study Director . 
Dose escalation may be stopped at any time based upon the Sponsor or Investigator’s clinical assessment or judgment. Upon completion of the DLT observational period (first week after 
dosing), the SRC will examine safety data through Week 1 for each dose cohort in combination 
with all available, previously accumulated safety data, as well as available PK data, if any, from 
all subjects enrolled in the study to date. All cohorts will enroll 8 subjects (safety data from at 
least 6 or 7 subjects would be needed for SRC meeting, in case a subject discontinues the study) , 
if no more than 2 out of 8 subjects experiences DLT as defined in the section 4.2.1, dose will be 
escalated to the next dose level.  
 Subject Stopping Criteria:  
Dosing will be permanently stopped for any individual subject experiencing any of the following: 
• Any SAE, regardless of causality to the study drug. 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL
Page 29 • Subject experience DLT. 
• Hypersensitivity or anaphylactic reaction following start of infusion. 
• Medical condition that  is judged by the Investigator as to jeopardize the subject’s safety if he or she 
continues to receive the study drug. 
• QTc prolongation defined as QTcF increasing ≥ 60 msec and persisting for at least 10 minutes or 
QTcF > 500 msec and persisting for at least 30 minutes, or episode of torsade de pointes. 
 Dose Escalation Stopping Criteria:  
Dose escalation will not occur if any of the following criteria are met: 
• Subject stopping rules met for ≥ 2 subjects in the same cohort suggesting to the 
Investigator that other subjects in the cohort are at risk for similar adverse drug 
reactions. 
• Any SAE as defined in the section 10.1 in any participant receiving study drug unless obviously not related. 
•  ≥2 out of 8 subjects experience toxicity ≥ Grade 3 as defined in the Food and 
Drug Administration (FDA) Guidance for Industry Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical 
Trials.  
The safety review will initially be performed on blinded data, and  if any of the above criteria are 
met, the cohort will be subsequently unblinded to all SRC members and the safety and tolerability reassessed. Upon unblinding, the dose may be determined to be safe and tolerable, on the basis of events observed in the OsrHSA vs. placebo groups, allowing for dose escalation to proceed. 
 
4.3 Rationale for Starting Dose and Maximum Dose Selection 
As there is no difference in in vivo efficacy, immunopharmacological activity, safety 
pharmacology, toxicology, and pharmacokinetic profiles observed between OsrHSA and 
HpHSA, OsrHSA is expected to have similar exposure and clinical effects as HpHSA in 
indications that are currently approved for HpHSA. The starting dose and the maximum dose for 
proposed US clinical trial of OsrHSA were selected based on the current clinical doses of 
HpHSA, which are in the range of 5 to 100 g (0.071 – 1.429 g/kg) [ Guidelines for Intravenous Albumin Administration at Stanford Health Care. Stanford Health Care.  Created: 03/2017 Pharmacy Department] depending on the condition for which HpHSA is used to treat, for example, 50 to 100 g, IV, over 4 hours, repeat at 4 to 12 hours intervals as needed, can be used to treat ovarian hyperstimulation syndrome.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 30 Regardin g the potential toxicity of host cell proteins, daily i.v. infusions  of 25  µg/kg HCP  
induced no clinical findings  in rats. Thus, the proposed 1.5 g (0.021 g/kg, contains 0.10 µg/kg  
possible HCP ) starting dose provides 40-fold safety margin from the  25 µg/kg HCP rat dose (4 
µg/kg  HED, converted based on BSA).  
In an ongoing  randomized, double blinded, positive-controlled Phase 1 single dose  and dose 
escalation study of OsrHSA in adult healthy volunteers  for safety, tolerability, PK and PD 
(PK/PD) study  in China, five healthy volunteer were administerd single dose of 2.5 g OsrHSA 
(35.7 mg/kg assuming body weight of 70 kg), IV. The data indicated that ADA, anti -HCP 
antibody are negative at 85 days ( 5 subjects)  of post -dosing. No cytokines promotion was fo und 
at 28 days ( 5 subjects)  of post -dosing. No allergic and hypersensitivity  symptom was observed 
during dosing or post dosing. One subject experienced abdominal pain and a transient 20 x 
elevation  in ALT/AST. The subject was recovered and the AEs were con sidered highly likely 
due to pre -existing cholelithiasis and cholecystitis by DSMB. Another subject was found a 
transient 2.4x ALT/AST elevation without any symptoms and signs. Please see M2.7 for the 
detailed clinical data . 
The next dose level s of 5.0 , 10, 15, and 20  g OsrHSA are being tested in healthy volunteer in 
China, data will be updated when data available.  
In summary, OsrHSA  has shown acceptable safety profile at dose level of 35.7 mg/kg. The 
proposed starting dose of 20 mg/kg in the current protocol is justified by 1.8 -fold lower than the 
tested dose in China and considered to be safe.  
5 PATIENT  POPULATION   
5.1 Number of Subjects and Description of Population  
This study will enroll up to 40 healthy male or female subjects , 8 subjects for each of 5 cohorts, 
18-55 years  old, or more  subjects might be recruited based on emerg ing data from this study and 
ongoing China clinical trial . Subject Selection and Numbering:  
5.2 Inclusion Criteria  
Subjects must meet all the following criteria to be enrolled in the trial:  
1. Able to understand and willing to sign the ICF  
2. Healthy male and female subjects , non-smokers , 18-55 years of age , non-smokers, or 
subjects must have been non -smoking for at least 3 months prior to their screening visit  
3. Has adequate venous access  
4. With no significant medical history, and in  good health as determined by detailed medical 
history  (neurological, endocrinal,  cardiovascular, pulmonary, hematological, immunologic, 
psychiatric, gastrointestinal, renal, hepatic, and metabolic disease ), full physical examination, 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 31 vital signs, 12 -lead electrocardiogram (ECG), urinalysis and laboratory tests at  screening.  For 
eligib ility purposes, abnormal laboratory or vital signs results may be repeated once if 
abnormal result is observed at the initial reading. Moreover, abnormalities found in the ECG 
may need to be confirmed by repeated measurements.  
5. Subjects must have adequate o rgan function according to the following laboratory  values:  
o Bone marrow function (absolute neutrophil count ≥1500/mm3 and platelet  count  
≥100,000/mm3) 
o Adequate liver function [alanine aminotransferase (ALT) ≤ 1.5 × 
upper limit normal (ULN) and alkaline phosphatase ≤ 1.5 × ULN, 
total bilirubin ≤1.5  mg/dL]  
o Adequate renal function creatinine clearance 60 mL/min based 
on Cockcroft - Gault  equation, or s erum creatinine level ≤1.5 
times the ULN . 
6. Be a female of non -childbearing potential (i.e., physiolo gically incapable of becoming 
pregnant, including any female who is 2 years post -menopausal and have an FSH > 
40mIU/mL, or surgically sterile [defined as having a bilateral oophorectomy, hysterectomy 
or tubal ligation]) or agree to one of the following to prevent pregnancy  and, if a woman of 
childbearing potential, have a negative urine pregnancy test at screening :  
- Practicing abstinence  
- If a sexually active woman of childbearing potential (sexually active with a non -sterile male 
partner ) agrees to pre vent pregnancy by using double methods of contraception as follow  
until at least 30 days  after the administration  of the investigational product:  
a. simultaneous use of intra -uterine contraceptive device, placed at least 4 weeks prior to 
study drug administr ation, and condom for the male partner;  
b. simultaneous use of hormonal contraceptives, starting at least 4 weeks prior to study drug 
administration and must agree to use the same hormonal contraceptive throughout the 
study, and condom for the male partner;  
c. simultaneous use of diaphragm with intravaginally applied spermicide and male condom 
for the male partner, starting at least 21 days prior to study drug administration.  
 
- Male subjects who are not vasectomized for at least 6 months  and who are sexually active 
with a non-sterile female partner must agree to use double method s of contraception below  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 32 from the first dose of randomized study drug until 90 days  after their dose and must not 
donate sp erm during their study participation period : 
a)  simultaneous use of a male condom and, for the female partner, hormonal contraceptives 
(used since at least 4 weeks) or intra -uterine contraceptive device (placed since at least 4 
weeks);  
b) simultaneous use of a male condom and, for the female partner, a diaphragm with 
intravaginally applied spermicide.  
7. Body mass index (BMI) 18-30 kg/m2 and body weight ≥  50.0 kg for males and  ≥ 45.0 kg  for 
females. 
8. Blood pressure ≤ 139/89 mm Hg .  
9. Subjects are able to follow the study protocol and complete the trial . 
10. At least 25% of the enrolled subjects will be of Asian descent, defined as Chinese, Japanese, 
Korean, Vietnamese, Hmong, and their offspring .  
 
5.3 Exclusion Criteria  
Subjects who meet any of the following criteria cannot be enrolled:  
1. History of severe infection within 4 weeks to dosing . 
2. Signs and symptoms of any active infection regardless of severity within 2 weeks prior to 
dosing.  
3. Meals & Dietary Restrictions: No seafood or high -fat food will be served during confinement 
in the clinical center  
4. Subjects who have any history of allergy to food or drug will be excluded ( Including 
allergies, hypersensitivity, or intolerance to rice or rice products )  
5. Use of any prescription  drugs ,  herbal supplements, or nonprescription drugs including oral 
anti-histamines (for seasonal allergies) within 1 month or 5 half -lives (whichever is longer) 
prior to study drug administration, or dietary supplements within 1 week prior to study drug 
administration , unless, in the opinion of the Investigator and Sponsor, the medication will not 
interfere with the study . Over -the-counter multivitamins will be permitted. If needed, 
paracetamol/acetaminophen may be used, but must be documented in the Conc omitant 
medications/Significant non -drug therapies page of the source data .  Any questions of 
concomitant medications should be directed to the Sponsor.  
6. Participation in a clinical research study involving the administration of an investigational or 
marke ted drug or device within 30  days prior to the first dosing, administration of a 
biological product in the context of a clinical research study within 90  days prior to the first 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 33 dosing, or conco mitant participation in an investigational study involving no drug or device 
administration.  
7. Donation of blood 12 week prior to dosing.  
8. Pregnant, or nursing females . 
9. A history of substance abuse, psychiatric and psychological condition that, in the judgment 
of the investigator, may interfere with the planned treatmen t and follow -up, affect subject 
compliance or place the subject at high risk from treatment -related complications  
10. A history of severe allergic reaction to any HpHSA component . 
11. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc F 
interval >450 milliseconds [ms])  
12. History of or active obstructive disease in biliary tract, liver, kidney  and spleen defined by 
ultrasound  
13. Subjects who test positive for hepatitis B or C. (no matter carriers or active will be excluded 
from the  study 
14. Subjects who test positive for Syphilis , Human immunodeficiency virus (HIV) positive will 
also be excluded from the  study   
15. Immunization with a live or attenuated vaccine is prohibited within 4 weeks prior to study 
drug administration . Seasonal influenza vaccines for injection are generally killed virus 
vaccines and are allowed; howe ver, intranasal influenza vaccines (e.g., FluMist®) are live 
attenuated vaccines and are not allowed)   
16. Positive Ig E and Ig G against rice at screening  
17. History of sig nificant alcohol abuse within one year prior to screening or regular use of 
alcohol within six months prior to the screening visit (more than fourteen units of alcohol per 
week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or positive  
alcohol breath test at screening  
18. History of significant drug abuse within one year prior to screening or use of soft drugs (such 
as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, 
phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine 
derivatives) w ithin 1 year prior to screening  
19. Positive urine drug screen , cotinine test, or alcohol breath test at screening  
20. Any reason which, in the opinion of the Qualified Investigator, would prevent the sub ject 
from participating in the study.  
5.4 Meals and Dietary Restrictions  
Subjects will receive a standard diet whilst resident in the clinical center.  For standardization 
purpose, the study drug infusion will start at least 30 minutes after subjects have been served a 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 34 light breakfast. No food will be allowed until at least 1 hour after the end of infusion. 
Standardized meals will be served at appropriat e times thereafter.  
Water will be provided ad libitum  at all times.  
In addition, subjects will be required to abstain from:  
• food containing poppy seeds within 24 hours prior to admission;  
• food or beverages containing xanthine derivatives or xanthine -related compounds (coffee, 
black/green tea, chocolate) or energy drinks from 48 hours prior dosing until EOS ; 
• dietary supplements within 1 week prior to study drug administration until EOS , unless, 
in the opinion of the Investigator and Sponsor, the dietary supplement will not interfere 
with the study;  
5.5 Tobacco, Alcohol  and Illicit Drugs  
Refrain from intake of alcoholic beverages from 72 hours prior to study treatment 
administration until Day 8 postdos e. After Day 8, subjects are discouraged from 
consuming alcohol until the completion of the study, but may consume no more 
than 1 unit of alcohol per day.  
Subjects will be required to abstain from using nicotine products, or soft or hard 
drugs from screeni ng and throughout the study.  
5.6 Medication  
Use of any prescription, herbal supplements, or nonprescription drugs will be prohibited within 1 
month or 5 half -lives (whichever is longer) prior to study drug administration  and until EOS, 
unless, in the opinion o f the Investigator and Sponsor, the medication will not interfere with the 
study . No concomitant drug therapy will be allowed during the study except one(s) required for 
the medical management of an adverse event.  
Any concomitant medication use other than the occasional use of acetaminophen will be 
evaluated on a case -by-case basis by the Principal Investigator or a physician. The use of 
hormonal contraceptives will be allowed and documented. All concomitant medication use will 
be documented.  
5.7 Activity  
Subje cts should refrain from strenuous exercise for 48 hours before admission to 
the clinical center and throughout the study.  Subjects may participate in light 
recreational activities during the study (eg, watching television, reading).  
Subjects will be advise d not to donate blood or plasma from at least 12 weeks 
before study drug administration and for at least 3 months after the last dose 
administration.   
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 35 For safety reasons, subjects will be required to remain semi -reclined  and avoid 
lying down or sleeping for the first 4 hours after the end of study drug infusion. 
However, failure of subjects to comply with these requirements does not 
constitute a deviation from the protocol if it is medically necessary, procedurally 
requir ed, or to go to the bathroom. When appropriate, subjects will be 
accompanied by a staff member during ambulation .   
5.8 Randomization and blinding  
Subjects in the clinical site will be 6:2 randomized to receive either the study 
product  or placebo  prior to dosing,  the randomization code will not be available 
to the Bioanalytical Division until the clinical and analytical phases have been 
completed  for each cohort . 
Both the principal investigator and subject s will be blinded as to whether a 
subject is receiving study product , or placebo . A designated person in the 
Investigational Pharmacy will dispense the appropriate drug accordingly.  The 
Safety Review Committee can request unblinded randomization scheme in order 
to evaluate the data.  
Each bottle  administered to subjects will have a unique code, and quick 
unblinding will be performed by Investigational Drug Pharmacy, the principal 
investigator, or the sponsor , should a medical emergency arise for a participant.  
Upon completion of the study participation, all subjects will be unblinded  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL 
Page 36 6 STUDY  INTERVENTION 
6.1 Study Drug Description 
OsrHSA drug product is presented as a slightly viscous, yellow to brownish clear liquid packed in Type I 
neutral borosilicate moulded glass vial capped with chlorobutyl rubber stopper with Polytetrafluoroethylene (PTFE)/Polyhexafluoroethylene film and plastic-aluminum seal. Each vial contains 10 g OsrHSA protein, 0.261 g sodium octanoate, 0.409 g sodium chloride, pH6.4~7.4. The total volume is 50 ml.  
Normal Saline (0.9% Sodium Chloride) will be used as the placebo. 
6.2 Study D rug Packaging and Labeling 
OsrHSA drug product is packed in Type I neutral borosilicate moulded glass vial capped with chlorobutyl 
rubber stopper with Polytetrafluoroethylene (PTFE)/Polyhexafluoroethylene film and plastic-aluminum seal. There will be a carton package. The labels for carton and vial are shown below. 
Recombinant human serum albumin from Oryza sativa (OsrHSA). 20% solution with 10g of drug.   
 Drug Storage and Handling 
OsrHSA drug product is stored at 2-8℃, protected from light. At time of use, the drug product vial is directly 
connected to the infusion line equipped with a 0.2µm in-line filter and administered via IV infusion.  
 Study D rug Compliance and Accountability 
The site should record and maintain shipping and receiving records of the study drug, and report to the Sponsor 
immediately any defect or issues with quality, quantity or interruption in cold-chain shipping.  
The site will maintain accurate dosage preparation records and should ensure that all pertinent/required 
information on the preparation and administration of the dose is captured in source documents, and appropriate 
dosing information is entered onto eCRFs. Such information should be made available to the Sponsor’s site 
monitoring representative(s) during monitoring visits.  
 Disposal and Destruction 
Upon termination of the study, or at the request of the sponsor, the pharmacist (or designee) must return the 
study drugs to Sponsor, unless it is destroyed at the clinical site as agreed upon by both the sponsor and the 
clinical site. 
 Treatment Allocation and Administration, Dosing R egimen  
This is a Phase 1 randomized, double blinded, placebo-controlled study. Subjects will be randomized. Both 
subjects and investigator will be blinded.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL 
Page 37 1. Parenteral drug products should be prepared by using appropriate aseptic technique, and inspected visually for 
particulate matter and discoloration prior to administration, whenever solution and container permit.  
2. Treatment Allocation and Administration: OsrHSA will be diluted with normal saline to a total volume of 200ml .  
The total infusion time will be 2hr ± 20min. 
 The OsrHSA infusion rate is lower than 2ml/min. The procedures used for administration are following: 
• First, set up intravenous channel and intravenous injection of 50 ml saline. The infusion rate for 
normal saline will be 5ml/min.  
• Second, OsrHSA or placebo will be administered via an infusion line equipped with a 0.2µm in-line 
filter. And monitor for infusion-related AEs during administration. The rate of intravenous should be lower than 2 ml/ min and cautions should be taken. Dose interruption based on intolerability will be captured in the monitoring of infusion start and stop times. 
• Third, flush with 50ml normal Saline after the dose. The infusion rate for normal saline will be 5ml/min.  
  
 
All dose administrations will be performed in the clinical center under the supervision of appropriately trained 
staff. 
Further detailed instructions on handling and administration of study drug is described in the separate Pharmacy 
Manual.  
6.3 Duration of Treatment 
This is a single dose study. • 50ml with 
normal Saline 
IV infusion 
1• Dilute OsrHSA
with normal saline to total volume 200 
ml for IV infusion 2• Flush with 50 
ml normal 
saline after 
the dose3
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL 
Page 38 6.4 Removal from Study Treatment and off-Study Criteria  
Participation in this research study is completely voluntary. Subjects are free to withdraw from this study at any 
time by informing the investigator. If a subject, for whatever reason, no longer appropriate to continue receiving 
study therapy, they will be notified and withdrawn from the study. Furthermore, if the subject is non-compliant 
(e.g. non-compliant with visits, concomitant medications.) they will be withdrawn from the study and a 
replacement subject may be recruited. 
Additionally, prior to removal from study, effort must be made to have all subjects complete a safety visit 
approximately 30 days following the last dose of study therapy.  
 Criteria for Removal from Study T reatment  
• Completion of protocol therapy 
• Participant requests to be withdrawn from the study 
• Investigator discretion 
• Lost to follow-up or noncompliance 
• AEs or safety concerns by Investigator or Sponsor  
• Positive alcohol test, cotinine test, or drug screen 
• Positive pregnancy test. 
 Off-Study Criteria 
Once a subject is taken off study, no further data can be collected.   
• Participant request to be withdrawn from study 
• Subject withdrawal from the follow-up period 
• Subject completed all protocol required follow-ups 
• Death 
• Screen failure 
 Subject  Replacement 
Subjects who do not receive the full dose of study drug, or who withdraw from the study or with 
significant protocol violations may be replaced at the discretion of the investigator after 
informing the Sponsor.
Sponsor: Wuhan Healthgen  Biotechnology Corporation  
                                               Date: June 15, 2019  
Protocol Number:                                                                                                               Version 1.0  
39  
 7 STUDY ASSESSMENT  AND EVALUATIONS  
7.1 Description of Assessment Procedures  
Below are additional descriptions of study assessments not detailed in Table 1 .  
Recording of A Es: AEs should be documented and recorded per Guidance for Industry Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 
Clinical Trials . After signing ICF and before  the administration , only SAEs related to stu dy 
intervention will be recorded. All AEs will be recorded once dosing starts and subjects must be 
followed for AEs for 30 days after the administration, or until all drug related toxicities have 
resolved, whichever is later. After 30 days only SAEs consid ered related to study treatment will 
continue to be recorded . 
7.2 Blood Samples for PK evaluations  
Blood samples will be collected at pre -dose, 0.5h after dose initiating,  EOI,  and 0.5h, 4h, 12h, 
24h (Day 2), 48h (Day 3), Day 5, Day 8, Day 15, Day 22, and Day 30 post EOI , from all subjects 
to determine the serum concentration of OsrHSA  using a validated immunoassay for PK 
analyses. Approximately 3 mL blood will be collected at each of the following time points. 
Serum will be separated and stored for bioanalysis  of OsrHSA  concentration with a validated 
assay. The exact/actual time to collect blood will be documented.  
An additional blood sample should be collected from subjects experiencing unexpected and/or 
serious AEs if possible . 
The sampling schedules are seen  in Table 1.  
 
7.3 Immunogenicity Evaluations  
Blood samples for ADA analyses will be collected at pre -dose, D8, D15, D22, and D30 post EOI  
.  
Sponsor: Wuhan Healthgen  Biotechnology Corporation  
                                               Date: June 15, 2019  
Protocol Number:                                                                                                               Version 1.0  
40  
 8 DATA COLLECTION AND MANAGEMENT  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site investigator. The investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported.  
Hardcopies of the study visit worksheets will be used as source document work sheets for 
recording data for each participant enrolled in the study.  Data recorded in the electronic case 
report form (eCRF) derived from source documents should be consistent with the data recorded 
on the source documents. All source documents should be  completed in a neat, legible manner to 
ensure accurate interpretation of data.   
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse 
reactions data) and clinical laboratory data will be entered into 21 CFR Part 1 1-compliant data 
capture system provided. The data system includes password protection and internal quality 
checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or 
inaccurate. Clinical data will be entered directly from the source documents.  
Only individuals who have received training on the EDC are allowed to make eCRF entries, 
corrections, and alterations. Training must be documented and a log of all EDC users and their 
rights within the system be maintained. The d ata management team will raise queries in the EDC 
system to resolve discrepancies. The Investigator must verify that all data entries in the eCRFs 
are accurate and correct.  
Any outstanding entries must be completed immediately upon notice. No blank sections should 
be left on CRF and explanations has to be recorded for all missing data. All source documents 
should be retained. All essential documents should only contain subjec t coded identifiers and no 
personal identifying information should be transmitted.  
8.1 Study Record Retentions  
After completion of the study and when all collected data are validated, the database will be 
locked, pursuant to the prior approval by the Sponsor ( or its designee). Final data will be 
extracted from the EDC system and delivered in the form of SAS® datasets. A Portable 
Document Format (PDF) copy of the eCRF will be produced for each study subject and included 
in the final delivery.  
All data obtained during the conduct of the protocol will be kept in secure network drives or in 
approved alternative sites that comply with sponsors/CROs security standards. Each Subject will 
have identifiers that will be kept at the study sites.  
If clinical site/sponsor becomes aware of loss or destruction of data due to  a major breach 
occurrence that has  jeopardized subject confidentiality and trial data, the IRB will be notified.  
Study documents should be retained for a minimum of 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 41 applications in an ICH region or until at least 2 years have elapsed si nce the formal 
discontinuation of clinical development of the study intervention. These documents should be 
retained for a longer period, however, if required by local regulations. No records will be 
destroyed without the written consent of the sponsor, if  applicable. It is the responsibility of the 
sponsor to inform the investigator when these documents no longer need to be retained.  
8.2 Protocol Deviations  
Investigators ascertain they will apply due diligence to avoid protocol deviations. Under no 
circumstanc es should the investigator contact the Sponsor  if any, monitoring the study to request 
approval of a protocol deviation, as no authorized deviations are permitted. If the investigator 
feels a protocol deviation would improve the conduct of the study this m ust be considered a 
protocol amendment, and unless such an amendment is agreed upon by the Sponsor  and 
approved by the IRB/IEC/REB it cannot be implemented. All significant protocol deviations will 
be recorded and reported in the CSR.  
It is the responsibil ity of the site investigator to use continuous vigilance to identify and report , 
when applicable,  deviations within 5  working days of identification of the protocol deviation, or 
within 5 working days of the scheduled protocol -required activity.  All devia tions must be 
addressed in study source documents and if applicable, in eCRFs and study reports, in 
coordination with the sponsor or their designated CRO.  Protocol deviations must be sent to the 
reviewing IRB per their policies. The site investigator is r esponsible for knowing and adhering to 
the requirements of the reviewing IRB.  
8.3 Publication and Data Sharing  
Both the use of data and the publication policy are detailed within the clinical study agreement.  
Intellectual property rights (and related matters)  generated by the Investigator and others 
performing the clinical study will be subject to the terms of a clinical study agreement that will 
be agreed between the Institution and the Sponsor or their designee.   
Sponsor: Wuhan Healthgen  Biotechnology Corporation  
                                               Date: June 15, 2019  
Protocol Number:                                                                                                               Version 1.0  
42  
 9 REGULATORY  HUMAN SUBJECT PROTECTION AND  
REGULATORY OVERSIGHT  
9.1 Informed Consent Processes and Documentation  
In obtaining and documenting informed consent, the investigator must comply with applicable 
regulatory requirements (e.g., 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56) and should 
adhere to ICH GCP. Prior to the beginning of the trial, the investigator should have the IRB’s 
written approval for the protocol and the written ICFs and any other written information to be 
provided to the participants.  Participants will be asked to  read and review IRB -approved ICFs 
and other written information .  ICF should include detailed description of study procedures, risk 
and benefits, directions, participant’s rights, compensation if applicable, and contact of Human 
Subject Protection Service s.  Additionally, investigator will explain the research study to the 
participant in terms suited to the participant’s comprehension and answer any questions that may 
arise. Investigator should explain their rights as research participants, study procedure s, risk and 
benefits, anticipated adverse effects.  Participants will have the opportunity to carefully review 
the written consent form and ask questions prior to signing. ICF should be signed prior to any 
interventions for the study. Participants must be informed that participation is voluntary and that 
they may withdraw from the study at any time, without prejudice . Participant will be given a 
copy of the signed consent form and the original consent form will be kept as a permanent 
record.  
9.2 Confidentiality  and Privacy  
Participant confidentiality and privacy is strictly held in trust by the participating investigators, 
their staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover 
testing of biological samples in addition to the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be 
held in strict confidence. No information concerning the study or the data will be released to any 
unautho rized third party without prior written approval of the sponsor.  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the sponsor, representatives of the 
Institutional Review  Board (IRB), regulatory agencies or pharmaceutical company supplying 
study product may inspect all documents and records required to be maintained by the 
investigator, including but not limited to, medical records (office, clinic, or hospital) and 
pharmac y records for the participants in this study. The clinical study site will permit access to 
such records.  
The study participant’s contact information will be securely stored at each clinical site for 
internal use during the study. At the end of the study, all records will continue to be kept in a 
secure location for as long a period as dictated by the reviewing IRB, Institutional policies, or 
sponsor requirements.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 43 Research data, which is for purposes of statistical analysis and scientific reporting, will be  
transmitted to and stored at the data management group at the designated CRO. This will not 
include the participant’s contact or identifying information. Rather, individual participants and 
their research data will be identified by a unique study identifi cation number. The study data 
entry and study management systems used by clinical sites and by CRO staff will be secured, 
and password protected. At the end of the study, all study databases will be de -identified and 
archived at the CRO or Sponsor until fu rther data integration with future studies of OsrHSA . 
 
9.3 Conflict of Interest  
The independence of this study from any actual or perceived influence, such as by the 
pharmaceutical industry, is critical.  Therefore, any actual conflict of interest of persons who 
have a role in the design, conduct, analysis, publication, or any aspect of this trial will be 
disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be 
required to have such conflicts managed in a way tha t is appropriate to their participation in the 
design and conduct of this trial.
Sponsor: Wuhan Healthgen  Biotechnology Corporation  
                                               Date: June 15, 2019  
Protocol Number:                                                                                                               Version 1.0  
44  
 10 SAFETY REPORTING  
10.1 Definition  of Adverse Event  
An adverse  event (AE) is defined as any reaction, side effect, or untoward event that occurs 
during the course of the clinical trial whether or not the event is considered related to the 
treatment or clinically significant.  
For this clinical trial, AEs will include any events reported by the subject , any new medical 
conditions, and symptoms , any new abnormal findings on  physical examination or laboratory 
evaluation. Additionally, any  worsening of a pre -existing condition or abnormality will also be 
considered as an AE.  
All AEs must be recorded on eCRF. All AEs must be followed return to baseline or stabilizes.  
Serious adverse  events  (SAE)  
A serious adverse event is defined as any adverse experience that meets any of the following 
criteria:  
• Results in death;  
• Is life -threatening  
• Requires hospitalization or prolongation of existing hospitalization.  Addition ally, 
complications occurring during hospitalization are also considered AEs.  
• Results in persistent or significant disability or incapacity (This definition  is not intended 
to include experiences of relatively minor medical significance such as uncomplicated 
headache, nausea, vomiting, diarrhea, influenza, or accidental trauma (e.g., sprained 
ankle) which may interfere or prevent everyday life functions but d o not constitute a 
substantial disruption.);  
Other important medical events that may not be immediately life -threatening or result in death or 
hospitalization but, when based on appropriate medical judgment, may jeopardize the subject or 
may require inter vention to prevent one of the outcomes in the definition of SAE listed above 
should also be considered SAEs. Medical and scientific judgment should be exercised in 
deciding whether expedited reporting is appropriate in such situations.  
The following hospi talizations are not considered to be SAEs because there is no “adverse event” 
(i.e., there is no untoward medical occurrence) associated with the hospitalization:  
• Hospitalizations for respite care  
• Planned hospitalizations required by the protocol  
• Hospital ization planned before informed consent (where the condition requiring the 
hospitalization has not changed post study drug administration)  
• Hospitalization for administration of study drug or insertion of access for administration 
of study drug  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 45 • Hospitalizat ion for routine maintenance of a device (e.g., battery replacement) that was in 
place before study entry  
 
Adverse Reaction   
Any AE caused by a drug  is considered an adverse reaction . 
10.2 Causality of AEs  
Causality assessment has become a common routine procedure in pharmacovigilance. Causality 
assessments can decrease disagreement between assessors, classify relationship likelihood and 
improvement of scientific evaluation.  
Limitations of causality assessme nt are following:  
It can NOT assess accurate quantitative measurement of relationship likelihood  
It can NOT distinguish valid from invalid cases  
It can NOT prove the connection between drug and event  
It can NOT quantify the contribution of a drug to the d evelopment of an adverse event  
All adverse events (AEs) must have their relationship to study intervention assessed by the 
clinician who examines and evaluates the participant based on temporal relationship and his/her 
clinical judgment. The degree of cert ainty about causality will be graded using the  2 categories 
below. In a clinical trial, the study product must always be suspect.  
Related :  The AE is known to occur with the study intervention, there is a reasonable possibility 
that the study intervention caused the AE, or there is a temporal relationship between the study 
intervention and event. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the study intervention and the AE.  
Not Related :  There is  not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention 
and event onset, or an alternate etiology has been established.  
10.3 Categorization of AEs  
AEs wil l be graded according to the FDA Guidance for Industry Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials ” and 
reported in the detail indicated on the CRF.  The definitions are as follows:  
Grad e 1 Mild : discomfort noticed, but no disruption to daily activity  
Grade 2 Moderate : discomfort sufficient to reduce or affect normal daily activity  
Grade 3 Severe:  Inability to work or perform normal daily activity    
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 46 Grade 4 Potentially Life -threatening  
10.4 Reporting of SAEs and Suspected Unexpected Serious Adverse Reactions (SUSARs)  
Any SAE, including death resulting from any cause, which occurs to any subject participating in 
this study must be reported by investigator to the sponsor within 24 hours  (and IR B as r equired) 
of first becoming aware of the SAE. The study sponsor will be responsible for notifying the FDA 
of any unexpected fatal or life -threatening suspected adverse reaction as soon as possible, but in 
no case later than 7 calendar days after the s ponsor's initial receipt of the information.  In 
addition, the sponsor must notify FDA and all participating investigators in an IND safety report 
of potential serious risks, from clinical trials or any other source, as soon as possible, but in no 
case lat er than 15 calendar days after the sponsor determines that the information qualifies for 
reporting  
SAEs will be collected by the investigator from day 1 through 30 days after the administration  of 
study medication. SAEs that occur within 30 days following cessation of the study treatment, 
must also be reported within the same timeframe. Any SAE that is judged by the investigator to 
be related to the study medication must be reported regardless o f the amount of time since the 
last dose received. Follow -up information collected for any initial report of an SAE must also be 
reported to the sponsor (or its designee) within 24 hours of receipt by the investigator. All SAEs 
will be followed until resol ution, stabilization of condition, or until follow -up is no longer 
possible.  To fully understand the nature of any SAE, obtaining follow -up information is 
important. Whenever possible, relevant medical records such as discharge summaries, medical 
consultat ions, reports of radiographic studies, and clinical laboratory reports should be obtained.  
In the event of death, regardless of cause, all attempts should be made to obtain the death 
certificate and any autopsy report, if performed. These records should b e reviewed in detail, and 
the investigator should comment on any event, lab abnormality, or any other finding, noting 
whether it should be considered a serious or non -serious AE, or whether it should be considered 
as part of the subject’s history. In addit ion, all events or other findings determined to be SAEs 
should be identified on the follow -up SAE form and the investigator should consider whether the 
event is related or not related to study drug.  
10.5 IRB Reporting  
The investigators will report to the IRB the following  according to the requirements of reviewing 
IRB: 
• All SAEs , except deaths due to progressive disease  
• Non-compliance  to GCP or protocol deviations as required by IRB  
IND Safety Reports and a ny unexpected incidences or problems during the trial may be also 
reportable to the IRB as per  IRB requirement.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 47 10.6 Quality Assurance and Quality Control  
Quality control (QC) procedures will be implemented  to assure that any missing data will be 
communicated with sites for clarification and resolution.  
Standard Operating Procedures (SOPs)  should be available to monitors. Monitors will verify that 
all the clinical trial procedures are conducted, documented and reported in compliance with the 
protocol, ICH, GCP , GLP, GMP and other applicable regulatory requirements .  
The investigational site will provide direct access to all trial related sites, source data/documents, 
and reports for the purpose of monitoring and auditing by the sponsor, and inspection by lo cal 
and regulatory authorities.  
10.7 Study Monitoring Plan  
Clinical site monitoring is conducted to ensure that the rights and well -being of trial participants 
are protected, that the reported trial data are accurate, complete, and verifiable, and that the 
conduct of the trial is in compliance with the currently a pproved protocol/amendment(s), with 
ICH GCP, and with applicable regulatory requirement(s).  
Monitoring for this study will be performed by the Sponsor.  
Details of clinical site monitoring will be  documented in a separate Study Monitoring Plan 
(SMP). The SMP describes in detail who will conduct the monitoring, at what frequency 
monitoring will be done, at what level of detail monitoring will be performed, and the 
distribution of monitoring reports.  In general monitoring visits would include pre -study visit s (to 
qualify the site and investigators), study initiation visit, interim visits at appropriate frequency 
based on recruitment speed and need to clean data for dose -escalation decisions, and study 
closeout visits after database lock.  
Independent audits may be conducted by the sponsor  to ensure monitoring practices are 
performed consistently across all participating sites and that monitors are following the SMP. 
Monitors are qualified by training and experience to monitor the progress of clinical trials. 
Personnel monitoring this study will not be affiliated in any way with the trial conduct .  
A monitor(s)/ sponsor representative (s) will meet with the investigator and his/her staff prior to 
the entrance of the first subject to review study procedures and met hods of recording study data. 
After enrollment of the first subject, a monitor(s)/sponsor representative(s)  will be assigned to 
periodically monitor each investigator site for study progress and to verify that standards of 
Good Clinical Practice (GCP) and/ or ICH guidelines were followed.  
The investigator is expected to prepare for the monitor visit, ensuring that all source documents, 
completed CRFs, signed consent forms and other study related documents are readily available 
for review.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 48 FDA regulations require the Investigators  to facilitate monitoring process . Monitors will evaluate  
adherence to the protocol, regulations, SOPs, human subject protection, study data, specifically 
data that could affect the interpreta tion of primary study e ndpoints . This is done through 
independent verification of study data with source documentation focusing on:  
• Informed consent process  
• Eligibility confirmation  
• Drug administration and accountability  
• Adverse events monitoring  
10.8 Study Closure  
The investigator may terminate the study at any time in the interest of subject welfare. The 
sponsor may terminate the study prematurely at any time. Reasons for the closure of an 
investigational site or termination of a study may include:  
• The Investigato r fails to comply with the protocol or ICH/GCP guidelines  
• Safety concerns  
• Inadequate recruitment of subjects by the investigator  
• Completion of the study  
If the clinical study is prematurely terminated or suspended, the sponsor or CRO representative 
will inform the investigator and the regulatory authorities of the termination/ suspension and the 
reasons for the termination/suspension as appropriate. The investigator should promptly notify 
the IEC/IRB of the termination or suspension and provide reasons. The sponsor reserves the right 
to close the investigational site or terminate the study in its entirety at any time, for reasonable 
cause.  
Premature termination of the study by either PI or sponsor will be governed under the terms of 
the contract between both parties.  
10.9 Safety Review Committee (SRC)  
To ensure  the safety  of study subjects  and integrity of the study data, a Safety Review 
Committee (SRC) consisting of the study Investigators , Study Director , designated Medical 
Monitor  and/or other key study pe rsonnel will convene to review cumulative data for the study.  
SRC will conduct dose decision teleconference meeting  before each dose escalation . 
Before each dose escalation, the Investigators, Study Director and Medical Monitor(s), together, 
will review t he safety data from the current cohort after  enough  subjects  (7-8) have completed 
the first week.  It will be determined whether escalation to the next dose level can proceed or 
whether dose level should be de -escalated.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 49 .  
  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL
Page 50 11 STATISTICAL CONSIDERATIONS  
11.1 General Statistical Considerations 
Descriptive statistics will be utilized for all safety, efficacy, and PK parameters. Data will be 
summarized using descriptive statistics (number of subjects, mean, and median, standard deviation, minimum and maximum) for continuous variables and using frequencies and 
percentages for discrete variables.  
In addition to descriptive summary, statistical testing will be performed to provide inferential 
summaries of group/subgroup comparison of endpoints. Univariate analyses will be conducted to determine the effects of key patient and disease characteristics on study endpoints, e.g., Two-
sample t-test or Wilcoxon rank sum test will be used for continuous variables as appropriate and 
Chi-square test or Fisher’s exact test for categorical variables. Kaplan-Meier method or log-rank 
test will be provided for time- to-event endpoints. For comparison of more than 2 groups, 
ANOVA test or Kruskal-Wallis test will be carried out. Multivariate analyses may be conducted 
to examining relationship between multiple variables and endpoints.  
11.2 Determination of Sample Size 
An estimated total of 40 subjects will enroll in this study. The sample size for this study was 
determined based on clinical, rather than statistical considerations. A projected sample size of 8 subjects per dosing cohort is considered to be of reasonable size to achieve the objectives of this 
single dose escalation trial. Other factors may contribute to the final sample size, which is 
dependent upon the observed safety and tolerability profile, and determines the number of subjects per dose cohort, number of replacements, as well as the number of dose escalations required to achieve the maximal proposed dose of the study drug. 
11.3 Population Analysis 
 PK and PD Population  
The PK population will include all subjects who have at least one post-dose blood sample providing evaluable PK data. 
 Safety Population  
The safety population will include all subjects who receive the investigational drug. The safety analyses population will be the primary population for evaluating treatment administration, compliance and safety in the study.  
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL
Page 51 11.4 Statistical Analysis 
 PK Analysis 
PK parameters will include T max, Cmax, AUC last, AUC ∞, t1/2, CL, and Vz. The concentration-time 
data will be summarized by descriptive statistics (n, mean, and standard deviation, coefficient of 
variation, median, minimum, maximum, and geometric mean) according to dosing cohort and time of the study. PK pa rameters will be estimated using a non-comp artmental method with 
WinNonlin (Phar sight Corp, Cary, North C arolina). Individual serum concentration of versus 
actual day will be tabulated and plotted by dose level (linear and log scales). Plots of the mean or 
median concentrations of OsrHSA will be presented by nominal day (linear and log scale) by 
dose level. If 3 cohorts complete in the study, linearity in PK parameters will be tested by fitting 
the model: log (C
max or AUC) =a+b*log(dose) +Dose. Dose-proportionality will be tested using 
Power Model.  
A population PK-based modeling approach may also be applied for PK characterization and PK 
covariate analyses. The steady state PK profile may be projected based on the population PK model. Population PK and PD data may be analyzed using modeling approaches and may also be pooled with data from other studies to investigate any association between investigational drug 
exposure and biomarkers or significant safety endpoints. Alternative dosing approach, e.g., body 
size-based or fixed dosing, may be evaluated using a population PK/PD approach. The results of 
these analyses, if performed, will be reported separately.  
 Safety Analysis 
Safety data will be summarized by treatment group using descriptive statistics. No formal 
inferential analyses are planned for safety comparisons. Continuous safety data will be 
summarized as sample size, mean, SD, minimum, and maximum, by scheduled time point and 
treatment for observed values and change from baseline values (as appropriate). Tabulations of frequencies and proportions, as appropriate will be used for the evaluation of categorical (qualitative) safety data.  
Adverse events will be classified by SOC and term using the Medical Dictionary of Regulatory 
Activities (MedDRA) coding dictionary. Incidence of treatment-emergent adverse events (TEAEs) will be summarized by SOC and preferred term for each treatment group. Incidence of TEAEs will also be summarized by severity and association with the study treatments. 
Concomitant medications will be presented in summary tables and listings. All safety data summaries will be based on the Safety Analysis Set. No statistical tests will be 
performed for the safety endpoints. 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number: US-HY1001 
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL
Page 52 Missing data will be treated as they are. No imputations of missing data are planned. 
 
 Immunogenicity Analysis 
All samples will first be analyzed for ADAs in a screening assay. Study samples with results 
below the screening cut-off will be reported as negative for ADAs. In the event of a positive 
result in the screening assay, samples will be analyzed in the confirmatory assay.  
The incidence of ADA will be summarized for all subjects who received at least one 
administration of study drug. Impact of ADAs on PK, PD, and safety of the study drug will be 
evaluated, if applicable.  
11.5 Tabulation of Individual Participation Data 
Data tabulations will summ arize the following numb ers of subjects:  
• Enrolled 
• Study drug t reatment dose re ceived 
• Evaluable for s afety  
• Protocol violations 
• Protocol completions 
• Withd raw from study due to: 
o Adverse event 
o Physician’ s recommendation 
o Withd rew consent 
o Lost to Follow-up 
o Other reasons a s collected on the eCRF  
 
 
 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 53 12 REFERENCES   
1. Peters T (1995) All About Albumin: Biochemistry, Genetics, and Medical Applications  
(Academic, San Diego).  
2. Alexander MR, Ambre JJ, Liskow BI, Trost  DC (1979) Therapeutic use of albumin.  
JAMA 241:2527 –2529.  
3. Hastings GE, Wolf PG (1992) The therapeutic use of albumin. Arch Fam Med 1:  281–
287. 
4. Marth E, Kleinhappl B (2001) Albumin is a necessary stabilizer of TBE -vaccine to avoid  
fever in children after v accination. Vaccine 20:532 –537. 
5. Tsuchida E, et al. (2009) Artificial oxygen carriers, hemoglobin vesicles and  albumin -
hemes, based on bioconjugate chemistry. Bioconjug Chem 20:1419 –1440.  
6. Cai C, Zhou K, Wu Y, Wu L (2006) Enhanced liver targeting of 5 -fluoro uracil using  
galactosylated human serum albumin as a carrier molecule. J Drug Target 14:  55–61. 
7. Subramanian GM, Fiscella M, Lamousé -Smith A, Zeuzem S, McHutchison JG (2007)  
8. Albinterferon alpha -2b: A genetic fusion protein for the treatment of chronic hepat itis C. 
Nat Biotechnol 25:1411 –1419.  
9. Xinhua News Agency (April 4, 2007) Drug watchdog tightens supervision of albumin  
medicine. Beijing Review, http://www.bjreview.com.cn/health/txt/2007 -
04/04/content_60856.htm.  
10. Erstad BL (1996) Viral infectivity of albumin and plasma protein fraction. 
Pharmacotherapy  16:996 –1001.  
11. Chamberland ME, Alter HJ, Busch MP, Nemo G, Ricketts M (2001) Emerging infectious  
disease issues in blood safety. Emerg Infect Dis 7(3, Suppl):552 –553. 
12. Zhang W, Hu D, Xi Y, Zhang M, Duan G (2006) Spread of HIV in one village in central  
China with a high prevalence rate of blood -borne AIDS. Int J Infect Dis 10:475 –480. 
13. Merten  OW (2002) Virus contaminations of cell cultures —A biotechnological view.  
Cytotechnology 39:91 –116. 
14. Latta L, et al. (1987) Synthesis and purification of mature human serum albumin from  E. 
coli. Biotechnology 5:1309 –1314.  
15. Sleep D, Belfield GP, Goodey AR (19 90) The secretion of human serum albumin from  
the yeast Saccharomyces cerevisiae using five different leader sequences. Biotechnology  
(N Y) 8:42 –46. 
16. Fleer R, et al. (1991) Stable multicopy vectors for high -level secretion of recombinant  
human serum albumin  by Kluyveromyces yeasts. Biotechnology (N Y) 9:968 –975. 
17. Kobayashi K, et al. (2000) High -level expression of recombinant human serum albumin  
from the methylotrophic yeast Pichia pastoris with minimal protease production  and 
activation. J Biosci Bioeng 89:5 5–61. 
18. Barash I, et al. (1993) Synthesis and secretion of human serum albumin by mammary  
gland explants of virgin and lactating transgenic mice. Transgenic Res 2:266 –276. 
19. Sijmons PC, et al. (1990) Production of correctly processed human serum albumin in  
transgenic plants. Biotechnology (N Y) 8:217 –221. 
20. Farran I, Sánchez -Serrano JJ, Medina JF, Prieto J, Mingo -Castel AM (2002) Targeted  
expression of human serum albumin to potato tubers. Transgenic Res 11:337 –346. 
Sponsor: Wuhan Healthgen Biotechnology Corporation  
Protocol Number:  US-HY1001  
 Date:  November 20, 
2019  
Version: 1.2  
  
 
 
CONFIDENTIAL  
Page 54 21. Fernández -San Millán A, Mingo -Castel A, Miller M, Daniell H (2003) A chloroplast  
transgenic approach to hyper -express and purify human serum albumin, a protein  highly 
susceptible to proteolytic degradation. Plant Biotechnol J 1:71 –79. 
22. Huang LF, Liu YK, Lu CA, Hsieh SL, Yu SM(2005) Production of human s erum 
albumin by  sugar starvation induced promoter and rice cell culture. Transgenic Res 
14:569 –581. 
23. Lau OS, Sun SS (2009) Plant seeds as bioreactors for recombinant protein production.  
Biotechnol Adv 27:1015 –1022.  
24. Boothe J, et al. (2010) Seed -based express ion systems for plant molecular farming.  Plant 
Biotechnol J 8:588 –606. 
25. Yang D, Guo F, Liu B, Huang N, Watkins SC (2003) Expression and localization of  
human lysozyme in the endosperm of transgenic rice. Planta 216:597 –603. 
26. Huang N, et al. (2008) Bioactive recombinant human lactoferrin, derived from rice,  
stimulates mammalian cell growth. In Vitro Cell Dev Biol Anim 44:464 –471. 
 